TITLE

Meta-Analysis: Increased Mortality Associated with Hepatitis C in HIV-Infected Persons Is Unrelated to HIV Disease Progression

AUTHOR(S)
Ting-Yi Chen; Ding, Eric L.; Seage III, George R.; Kim, Arthur Y.
PUB. DATE
November 2009
SOURCE
Clinical Infectious Diseases;11/15/2009, Vol. 49 Issue 10, p1605
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. It is unclear whether coinfection with hepatitis C virus (HCV) increases mortality in patients with human immunodeficiency virus (HIV) infection during the era of highly active antiretroviral therapy (HAART). With use of a meta-analysis, we estimated the effect of HCV infection on HIV disease progression and overall mortality in the pre-HAART and HAART eras. Method. The PubMed and EMBASE databases were searched for studies published through 30 April 2008. Additional studies were identified from cited references. Studies reporting disease progression or mortality among HCV-HIV coinfected patients were selected. Cross-sectional studies, studies without HCV-negative control subjects, and studies involving children and/or patients who had undergone liver transplantation were excluded. Two authors reviewed articles and extracted data on the demographic characteristics of study populations and risk estimates. Meta-regression was used to explore heterogeneity. Results. Ten studies from the pre-HAART era and 27 studies from the HAART era were selected. In the pre- HAART era, the risk ratio for overall mortality among patients with HCV-HIV coinfection, compared with that among patients with HIV infection alone, was 0.68 (95% confidence interval [CI], 0.53-0.87). In the HAART era, the risk ratio was 1.12 (95% CI, 0.82-1.51) for AIDS-defining events and 1.35 (95% CI, 1.11-1.63) for overall mortality among coinfected patients, compared with that among patients with HIV monoinfection. Conclusions. HCV coinfection did not increase mortality among patients with HIV infection before the introduction of HAART. In contrast, in the HAART era, HCV coinfection, compared with HIV infection alone, increases the risk of mortality, but not the risk of AIDS-defining events. Future studies should determine whether successful treatment of HCV infection could reduce this excess risk of mortality in coinfected patients.
ACCESSION #
45139533

 

Related Articles

  • T Cell Dynamics and the Response to HAART in a Cohort of HIV-1-Infected Elite Suppressors. Sedaghat, Ahmad R.; Rastegar, Darius A.; O'Connell, Karen A.; Dinoso, Jason B.; Wilke, Claus O.; Blankson, Joel N. // Clinical Infectious Diseases;12/1/2009, Vol. 49 Issue 11, p1763 

    Elite controllers or suppressors are untreated human immunodeficiency virus type 1 (HIV-1)-infected patients who maintain undetectable viral loads. In this study, we show that most elite suppressors do not experience significant changes in T cell counts over a 10-year period. Interestingly,...

  • The Evolution of Coreceptor Tropism in HIV-infected Patients Interrupting Suppressive Antiretroviral Therapy. Waters, Laura J.; Scourfield, Andrew T.; Marcano, Marie; Gazzard, Brian G.; Bower, Mark; Nelson, Mark; Stebbing, Justin // Clinical Infectious Diseases;3/1/2011, Vol. 52 Issue 5, p671 

    CCR5 antagonists may provide a well-tolerated switch option for patients experiencing tolerability or toxicity of their antiretroviral regimen. We analyzed stored samples from patients undergoing planned treatment interruptions for reasons other than virological failure, in order to analyze...

  • NIGELLA SATIVA CONCOCTION INDUCED SUSTAINED SEROREVERSION IN HIV PATIENT. Adekunle Onifade, Abdulfatah; Jewell, Andrew Paul; Adeola Adedeji, Waheed // African Journal of Traditional, Complementary & Alternative Medi;2013, Vol. 10 Issue 5, p332 

    Nigella sativa had been documented to possess many therapeutic functions in medicine but the least expected is sero-reversion in HIV infection which is very rare despite extensive therapy with highly active anti-retroviral therapy (HAART). This case presentation is to highlight the complete...

  • Does HCV make HIV infection worse? Mascolini, Mark // Research Initiative/Treatment Action!;Summer2014, Vol. 19 Issue 1, p20 

    The article discusses impact of hepatitis C virus (HCV) infection on HIV infection. Topics discussed include impact of HCV infection on mortality of HIV people, on response to combination antiretroviral therapy (cART), and on clinical outcomes and progression to AIDS. Two U.S. studies on HCV/HIV...

  • Highly Active Antiretroviral Treatment and Children. Nachman, Sharon // Clinical Infectious Diseases;11/15/2011, Vol. 53 Issue 10, p1035 

    The author reflects on the study related to the effectiveness of highly active antiretroviral treatment (HAART) in reducing the mortality of patients including children and adults affected with human immunodeficiency virus (HIV). He appreciates the authors of the study for conducting a well...

  • Penetration and Effectiveness of Antiretroviral Therapy in the Central Nervous System. Letendre, Scott; Ellis, Ronald J.; Best, Brookie; Bhatt, Archana; Marquie-Beck, Jennifer; LeBlanc, Shannon; Rossi, Steven; Capparelli, Edmund; McCutchan, J. Allen // Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry;Jun2009, Vol. 8 Issue 2, p169 

    Combination antiretroviral therapy (ART) has markedly reduced morbidity and mortality among HIV-infected individuals but not the prevalence of HIV-associated neurocognitive disorders (HAND). Several conditions may be responsible for the high prevalence of cognitive impairment, including...

  • Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management. Gutierrez, Absalon; Balasubramanyam, Ashok // Endocrine (1355008X);Feb2012, Vol. 41 Issue 1, p1 

    HIV-infected patients on highly active antiretroviral therapy (HAART) have increased prevalence of a number of chronic metabolic disorders of multifactorial but unclear etiology. These include disorders of lipid metabolism with or without lipodystrophy, insulin resistance, and an increased...

  • Does antiretroviral therapy for HIV reduce the risk of developing multiple sclerosis? van der Kop, Mia L. // Journal of Neurology, Neurosurgery & Psychiatry;Jan2015, Vol. 86 Issue 1, p3 

    The article presents a case study that examines the association of HIV and its treatment with antiretroviral therapy (ART) on multiple sclerosis (MS). Topics discussed include use of data of HIV patients between 1999 and 2011 followed up with records of MS, authors of the study showing that the...

  • Are All Subtypes Created Equal? The Effectiveness of Antiretroviral Therapy against Non-Subtype B HIV-1. Pond, Sergei L. Kosakovsky; Smith, Davey M. // Clinical Infectious Diseases;5/1/2009, Vol. 48 Issue 9, p1306 

    The article reports on the study regarding the effectiveness of modern combination of antiretroviral therapy against non-subtype B HIV-1 in the U.S. It states that the study examined the rates of viral suppression with antiretroviral therapy during infection with subtypes A, C, and D and with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics